~~<i id='87BC6F76A9'><strike id='87BC6F76A9'><tt id='87BC6F76A9'><pre id='87BC6F76A9'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：entertainment 2025-10-06 19:28:29 Page View：68

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare solvency divides Republicans at the presidential debate
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

explore

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Medicare slashes safety net hospital payments by nearly $1 billion

Thefederalgovernmentwillpayhospitalsthattreatpooranduninsuredpatientsalmost$1billionlessnextyear.Ado

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

FDA approves Sage Therapeutics’ rapid

AndrewHarnik/APTheFoodandDrugAdministrationonFridayapprovedanew,rapid-actingmedicinemadebySageTherap